Rigosertib

Rigosertib
Names
	IUPAC name 2‐[(2‐Methoxy‐5‐{[(E)‐2‐(2,4,6‐trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid
	Other names ON-01910
Identifiers
CAS Number	1225497-78-8;
3D model (JSmol)	[1]: Interactive image;
ChEBI	CHEBI:145417;
ChEMBL	ChEMBL1241855; ChEMBL2013119;
ChemSpider	5293927;
IUPHAR/BPS	7833;
KEGG	D10154;
PubChem CID	6918736;
CompTox Dashboard (EPA)	DTXSID30207984 ;
	SMILES [2]: COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O;
Properties
Chemical formula	C21H25NO8S
Molar mass	451.49 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[3] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[4]

Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

Mechanism

Rigosertib is a microtubule-destabilizing agent.[5]

gollark: Haiku even has a working browser; amazing, right?

gollark: https://www.redox-os.org/

gollark: https://www.haiku-os.org/

gollark: Why not try Haiku or Redox?

gollark: Well, enjoy.

References

"physical and chemical data on chemispider website".
"physical and chemical data on chemispider website".
"Onconova Therapeutics". Retrieved 2019-04-26.
https://clinicaltrials.gov/ct2/show/NCT01928537
Jost, M (2017). "Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent". Molecular Cell. 68 (1): 210–223.e6. doi:10.1016/j.molcel.2017.09.012. PMC 5640507. PMID 28985505. Retrieved 29 May 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "physical and chemical data on chemispider website".

[2] "physical and chemical data on chemispider website".

[3] "Onconova Therapeutics". Retrieved 2019-04-26.

[4] ttps://clinicaltrials.gov/ct2/show/NCT01928537

[5] Jost, M (2017). "Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent". Molecular Cell. 68 (1): 210–223.e6. doi:10.1016/j.molcel.2017.09.012. PMC 5640507. PMID 28985505. Retrieved 29 May 2018.